Paclitaxel is a drug commonly used to treat breast cancer. In this study, researchers are evaluating the safety and effectiveness of adding another drug called dasatinib to paclitaxel treatment in women with metastatic breast cancer.
In the phase I portion of the study, they will find the highest dose of dasatinib that can be given safely with paclitaxel in these patients. In the phase II portion, they will assess the effectiveness of the combination against breast cancer.
Dasatinib is approved for the treatment of certain types of leukemia, but it is being evaluated for its effectiveness against other cancers. Laboratory studies have shown that it has an anticancer effect on breast cancer cells. Dasatinib is thought to cause cancer cells to die by inhibiting a protein called SRC. It is a pill that is taken by mouth once daily.